ELREXFIO® (elranatamab)

ELREXFIO (elranatamab) ▼ Patient Card

▼This medicinal product is subject to additional monitoring.

Carry this card with you at all times. **SHOW THIS CARD** to any healthcare provider involved in your care and if you go to the emergency room.

IMPORTANT SAFETY INFORMATION FOR PATIENTS RECEIVING TREATMENT WITH ELREXFIO

+ IMPORTANT SAFETY INFORMATION

FOR THE PATIENT

Call your healthcare provider or get emergency help right away if you have any of these symptoms:	
• Fever (38°C or higher) • Difficulty breathing • Chills • Headache • Low blood pressure • Feeling dizzy • Fast heartbeat • Increased level of liver enzymes in the blood	• Confusion • Feeling less alert • Trouble speaking or writing • Numbness and tingling (feeling like "pins and needles") or loss of feeling
You should always ask your doctor about taking other medications while taking ELREXFIO.	

IMPORTANT TO REMEMBER: You may be asked to remain within proximity of a healthcare facility so your healthcare provider can monitor you for signs and symptoms daily for 48 hours after administration of each of the first 2 step-up doses. If you have **any** of these symptoms call your doctor or seek emergency medical attention right away! These are not all of the possible symptoms of ELREXFIO. Tell your doctor if you have any symptom that bothers you or does not go away.

FOR HEALTHCARE PROVIDERS

IMPORTANT SAFETY INFORMATION YOU SHOULD KNOW: ELREXFIO therapy can cause cytokine release syndrome (CRS) or neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) which may be fatal or life threatening. CRS may involve multiple organ systems.

This Patient has received ELREXFIO.

Name of ELREXFIO Treating Oncologist: _____
Office Phone Number: _____
After Hours Phone Number: _____
Healthcare Setting Name: _____

Dates of ELREXFIO Injections:

- **Step-up Dose 1 _____**
- **Step-up Dose 2 _____**
- **First Full Dose _____**

For any side effects please report to the Medicines Authority at http://www.medicinesauthority.gov.mt/adrportal and send by post or email to;
P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000
E: postlicensing.medicinesauthority@gov.mt

or you may report to the local representative of Pfizer Hellas S.A.:
Vivian Corporation Ltd., Tel: +356 21344610 or directly to Pfizer's web portal at https://www.pfizersafetyreporting.com.